Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

PHVS
Pharvaris N.V.
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
16.47USD+3.520%(+0.56)40,381
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 16, 2025 8:31:30 AM EDT
15.91USD0.000%(0.00)1,000
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 22, 2021
08:10AM EST  Pharvaris Announces Changes to its Board of Directors   GlobeNewswire Inc
Nov 10, 2021
08:19AM EST  Pharvaris Q3 2021 Cash And Cash Equivalents   Benzinga
08:10AM EST  Pharvaris Reports Third Quarter 2021 Financial Results and   GlobeNewswire Inc
Sep 3, 2021
08:00AM EDT  Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in the following three upcoming investor conferences in September:   GlobeNewswire Inc
Jul 30, 2021
08:09AM EDT  Pharvaris Q2 EPS (0.94), Up From   Benzinga
08:00AM EDT  Pharvaris Reports Second Quarter 2021 Financial Results and   GlobeNewswire Inc
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 9, 2021
06:10PM EDT  Pharvaris Presents Clinical Data on Oral PHA121 Supporting the   GlobeNewswire Inc
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jul 2, 2021
07:38AM EDT  The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures   Benzinga
Jul 1, 2021
07:08AM EDT  Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021   Benzinga
07:00AM EDT  Pharvaris to Present PHA121 Clinical Data for Oral Treatment of   GlobeNewswire Inc
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 11, 2021
08:00AM EDT  Pharvaris Announces Annual Meeting of Shareholders   GlobeNewswire Inc
Jun 4, 2021
03:45AM EDT  Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for   GlobeNewswire Inc
May 26, 2021
08:12AM EDT  Pharvaris Q1 EPS (0.66); Cash And Equivalents Of 238.3M For Quarter Ended Mar. 31   Benzinga
08:00AM EDT  Pharvaris Reports First Quarter 2021 Financial Results and   GlobeNewswire Inc
May 19, 2021
07:30AM EDT  The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
07:00AM EDT  -- Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral products for HAE patients   GlobeNewswire Inc
Apr 29, 2021
05:07PM EDT  Pharvaris Cash, Cash Equivalents 98.6M As Of Dec. 31, 2020, FY20 Loss 26M   Benzinga
04:53PM EDT  Pharvaris Says Had Cash And Equivalents Of 98.6M   Benzinga
Apr 21, 2021
08:01AM EDT  Pharvaris Announces FDA Acceptance Of IND Application For Prophylactic Treatment Of HAE Using PHVS416   Benzinga
08:00AM EDT  Pharvaris Announces FDA Acceptance of IND Application for   GlobeNewswire Inc
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Mar 4, 2021
08:00AM EST  Pharvaris to Participate in BioCapital Europe   GlobeNewswire Inc
Mar 2, 2021
01:33PM EST  B of A Securities Initiates Coverage On Pharvaris with Neutral Rating, Announces Price Target of $41   Benzinga
11:11AM EST  Oppenheimer Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $48   Benzinga
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021   Benzinga
07:58AM EST  Morgan Stanley Maintains Overweight on Pharvaris, Announces $51 Price Target   Benzinga
07:44AM EST  SVB Leerink Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $50   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 26, 2021
08:09AM EST  Pharvaris Reports First Patient Dosed In RAPIDe-1 Phase 2 Trial Of PHVS416 For On-Demand Treatment Of Hereditary Angioedema   Benzinga
08:00AM EST  Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study   GlobeNewswire Inc
Feb 23, 2021
07:25AM EST  The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts   Benzinga
Feb 19, 2021
10:06AM EST  Pharvaris Says Presents Pharmacodynamic Activity Of Oral PHA121, Under Development For Treatment Of HAE, At AAAAI Annual Meeting   Benzinga
10:00AM EST  Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under   GlobeNewswire Inc
Feb 9, 2021
04:05PM EST  Pharvaris Announces Closing of Initial Public Offering   GlobeNewswire Inc
Feb 5, 2021
12:00PM EST  Pharvaris Shares Open For Trade At $25; IPO Priced At $20/Share   Benzinga
10:21AM EST  Pharvaris Shares Will Open For Quote At 11 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST; IPO Priced At $20/Share   Benzinga
Feb 4, 2021
08:08PM EST  Pharvaris Announces Pricing of Upsized Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC